All studies
RecruitingHuman Pharmacology (Phase I)- OtherInterventional

GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-001 after subcutaneous administrations to healthy subjects (MONOSqut trial).

Ulcerative colitis is a long-term condition that causes painful swelling and sores in the bowel. Researchers are developing a new medicine called GRT-001 to help treat it in the future. Before testing it on patients, scientists must first make sure it is safe. This study is for healthy adult volunteers. It is an early-stage clinical trial designed to see how the body absorbs, breaks down, and removes GRT-001. Participants will receive either the study drug or a dummy injection (a placebo) given under the skin. Doctors will carefully monitor volunteers for any side effects and check how different dose levels behave in the body. Although taking part will not directly improve a participant's health, it provides vital clues that could lead to better treatments for people living with gut conditions.

At a glance

Status
Recruiting
Phase
Human Pharmacology (Phase I)- Other
Sponsor
Granite Bio AG
Enrolment target
40
Start
15 Apr 2026

What is this study about?

Ulcerative colitis is a chronic bowel condition where parts of the digestive tract become red, swollen, and painful. This can lead to tummy cramps, bleeding, and frequent trips to the toilet. Finding new and better treatments is essential to give people living with this illness more options to control their symptoms.

This trial is looking at an experimental drug known as GRT-001. Because the medicine is still very new, doctors need to carry out an early 'Phase 1' study. This means testing the drug in a small group of healthy volunteers first, rather than people who are currently unwell. The goal is to check how safe it is and how well the human body tolerates it.

The study also aims to measure how the medicine moves through the bloodstream and how long it stays in the body. Different groups of volunteers will receive gradually increasing doses under close medical supervision. This allows doctors to find a safe and sensible dose before testing it in patients with ulcerative colitis in future trials.

Key takeaways

  • This is an early-stage safety study for a potential new ulcerative colitis medicine called GRT-001.
  • The trial is open to healthy adults aged 18 and over.
  • The medicine is given as an injection under the skin.
  • Participants may receive either the active study drug or a dummy injection (placebo).
  • Volunteers will be closely monitored with regular health checks to watch for any side effects.

Who may be eligible?

This study is looking for healthy adult volunteers aged 18 and older. Both men and women are welcome to apply.

Because this is an early safety trial, volunteers must generally be in good overall health. You should not have serious long-term medical conditions, heart problems, or active infections.

The research team will carry out standard health checks before you can join. These checks make sure that taking part is as safe as possible for you and that your body can handle the study medicine.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I consider myself to be in good overall health.
  3. I do not have chronic bowel conditions or serious ongoing illnesses.
  4. I am able to attend clinic appointments for health checks and tests.
  5. I am comfortable receiving an injection under the skin.
Answer every question to see your result.

What does participation involve?

Taking part in this study involves receiving the study medicine as an injection just under the skin (a subcutaneous injection). Some volunteers will receive the real medicine, while others will get a placebo, which looks identical but contains no active drug. Neither you nor the study team will know which one you receive until the trial ends.

You will need to attend a clinic where doctors and nurses can observe you closely. You can expect regular health checks, such as blood tests, urine tests, heart traces (ECGs), and blood pressure checks. The study team will explain exactly how many visits you will need to make, whether any overnight stays are required, and how long they will follow up on your health after your injection.

Potential risks and benefits

Because you must be healthy to join, taking part will not provide any direct medical benefit to you. However, your involvement will help scientists learn whether this medicine could help people with bowel disease in the future. As with any new medicine, there is a risk of unexpected side effects or mild reactions where the injection is given, such as redness or soreness. You will be monitored closely by medical staff throughout, and you are free to leave the trial at any time without giving a reason.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Germany

Common questions

What is a placebo?

A placebo is a harmless dummy treatment that looks just like the real medicine but has no active ingredients. It helps doctors see if changes in health are really caused by the new drug.

Why is the trial being done in healthy people rather than patients?

Testing new medicines in healthy volunteers first allows scientists to check their safety and how the body handles them without the added complication of an existing illness.

How is the medicine given?

The medicine is given as a simple injection just under the skin, similar to how insulin is injected.

Will I be paid for taking part?

Phase 1 trials with healthy volunteers often provide payment or cover travel expenses for your time and effort. The research team will give you details about this.

Can I leave the study early if I change my mind?

Yes. Joining a clinical trial is entirely voluntary, and you can withdraw at any point without your future care being affected.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "GRT-1C102: A randomized, double-blind, placebo-controlled do…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.